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Abstract 
While the benefits of combined antiretroviral therapy have revolutionized the life expectancy of 
patients infected with the human immunodeficiency virus, treatment-associated toxicity is frequently 
observed. Abacavir is a nucleoside reverse transcriptase inhibitor associated with acute toxic events, 
such as hypersensitivity reactions. In addition, its long-term use has increasingly been recognized as 
associated with an increased risk of myocardial infarction. While the mechanisms underlying abacavir-
induced hypersensitivity and cardiotoxicity are not fully understood, abacavir bioactivation to a reactive 
aldehyde metabolite is thought to play a crucial role in this context. However, as a short lived specie, 
in vivo, its formation has so far eluded detection. Our initial hypothesis was that it could be efficiently 
trapped by N-terminal valine of hemoglobin, forming N-terminal-valine-abacavir adducts. 
With the ultimate goal of gain insight into the role of abacavir metabolism in abacavir-induced 
toxicity, the present work was focused on obtaining evidence for the abacavir bioactivation to a 
reactive aldehyde metabolite, in human immunodeficiency virus - infected patients, and on the 
evaluation of this reactive metabolite ability to undergo protein modification. To address these issues: 
1) abacavir-Edman standards were prepared to monitor the presence of these adducts in vivo; 2) the 
presence of abacavir-Edman adduct was screened in Wistar rats, for optimization of analytical 
method; and 3) in patients infected with the human immunodeficiency virus. The experimental 
approach used, involving N-Alkyl Edman degradation, for specific detachment of N-terminal-valine-
abacavir adducts from protein, followed by liquid chromatography-electrospray ionization tandem 
mass spectrometry analysis of detached abacavir-Edman adducts, upon comparison with standards 
prepared in vitro, allowed the unequivocal identification of these adducts in animal and human 
samples. These results represent the first report on the involvement of a conjugated aldehyde 
intermediate in the metabolic activation of abacavir in man. Whereas this evidence does not imply an 
exclusive relation between abacavir-Edman adducts and abacavir toxicity, the search for causal 
relationships between the formation of abacabir-derived protein adducts and the occurrence of 
abacavir-induced toxic events in patients is worth pursuing, and is currently underway, towards the 
clarification of mechanism(s) of abacavir-induced toxicity.  
 
 
 
Keywords: Abacavir, aldehyde metabolite, biomarker, cardiotoxicity, drug bioactivation, 
hypersensitivity.
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Resumo 
Apesar da terapêutica antiretroviral combinada ter revolucionado a esperança de vida de doentes 
infectados pelo vírus da imunodeficiência humano, a toxicidade associada ao tratamento é 
frequentemente observada. O abacavir é um nucleósido inibidor da transcriptase reversa que está 
relacionado com eventos tóxicos agudos, tais como reacções de hipersensibilidade. A sua utilização a 
longo prazo tem sido também associada a um aumento do risco de enfarte do miocárdio. Apesar dos 
mecanismos subjacentes à hipersensibilidade e à cardiotoxicidade induzidas pelo abacavir não serem 
completamente compreendidos. A bioactivação do fármaco a um metabolito aldeídico reactivo tem 
sido frequentemente apontada como tendo um papel crucial neste contexto. No entanto, a detecção 
deste metabolito in vivo ainda não foi conseguida, provavelmente devido ao curto tempo de vida 
deste tipo de metabolitos em condições fisiológicas. Como hipótese inicial, equacionou-se que este 
intermediário poderia ser armadilhado pela valina N-terminal da hemoglobina, formando um aduto 
covalente passível ser identificado/quantificado.  
Tendo como objectivo global a elucidação do papel do metabolismo do abacavir na toxicidade 
induzida por este fármaco, o presente estudo visou a obtenção de evidencias para a ativação do 
abacavir a um aldeído reativo, em doentes infectados pelo vírus da imunodeficiência humano, e a 
avaliação do potencial deste metabolito reactivo para modificar covalentemente proteínas. Para 
alcançar estes objectivos:1) foram preparados sinteticamente padrões dos adutos de abacavir para 
monitorar a presença destes in vivo;  2) foi investigada a presença destes adutos em ratos Wistar 
expostos ao abacavir, com o vista à optimização da técnica analítica para a identificação/quanticação 
de adutos; 3) foi investigada a presença dos adutos em doentes. Através de um procedimento 
experimental que envolveu a libertação selectiva do aduto, por degradação de Edman da valina N-
terminal, seguida da análise do aduto libertado por cromatografia líquida acoplada a espectrometria 
de massa com ionização por electrospray, e comparando com os padrões, foi possível identificar 
inequivocamente estes adutos in vivo. Estes resultados representam a primeira evidência do 
envolvimento de um aldeído conjugado na activação metabólica do abacavir no homem. Embora 
estes resultados não impliquem uma relação exclusiva entre a formação destes adutos e a toxicidade 
induzida pelo abacavir, sublinham a importância do estabelecimento de correlações entre a 
presença/concentração destes adutos e a ocorrência de eventos tóxicos. Atualmente, mais trabalho 
está a ser desenvolvido com o objectivo de esclarecer os mecanismos subjacentes à toxicidade do 
fármaco. 
 
Palavras-chave: Abacavir, bioativação de fármacos, biomarcadores, cardiotoxicidade, 
hipersensibilidade, metabolito aldeídico. 
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1.1 Human Immunodeficiency Virus Infection and the combined antiretroviral 
therapy 
More than thirty years have passed since human immunodeficiency virus (HIV)-infection epidemic 
began. However, this infection is still a serious worldwide public health problem. Nevertheless, the 
success of the combined antiretroviral therapy (cART) changed dramatically the prognosis of this 
infection, which is currently perceived as a chronic disease, particularly in the developed countries 
(Mehellou and De Clercq, 2010). At the end of 2010, 6.65 million people were on cART and this 
number is still increasing (WHO et al., 2011). Despite its indisputable benefits, cART life-long use 
raises concerns about its adverse effects, especially the long-term toxic effects. This potential toxicity 
of antiretroviral drugs can have a negative impact on clinical outcomes, ultimately affecting the quality 
of life and life expectancy of the patients. Moreover, the management of toxicity outcomes may require 
additional hospital visits and admissions, increasing the economic burden on already strained medical 
care systems. Thus, an understanding of the mechanisms underlying drug toxicity is essential for 
establishing dependable risk-benefit relationships that can guide decisions on treatment options. 
The HIV-infection can be considered as having four main stages.  Following the primary infection, 
there is a clinical latent period, asymptomatic, with active viral replication associated with a 
progressive destruction of the CD4 cells. This stage can last an average of 8-11 years, depending on 
several factors including the person´s health status and life style.  In this period of latency, there are 
enough immune cells to afford an immune response against the infection. But, eventually, a significant 
number of T cells are destroyed and the rate of production of these cells cannot follow the rate of its 
destruction, and the patient comes to a symptomatic stage. The cART is recommended to begin in this 
stage, according to the national (DGS, 2012) and international guidelines (EACS, 2011), when CD4 
count is bellow 350 cell/mm3. CD4 counts should be obtained every 3-6 months during periods of 
clinical stability, and more frequently should symptomatic disease occur. If CD4 count drops to 
baseline or below 50% of increase from pre-treatment (aprox. 30 cells.mm-3) then the cART should be 
changed. The maintenance of sequential viral load values < 150,000 copies/ml is associated with 
higher short-term survival rates, thus higher viral load is also a criteria to start the cART. Viral load is 
currently the preferred method for monitoring the response to cART. There should be at least 1 log 
reduction in viral load, preferably to less than 10,000 copies/ml HIV-RNA within 2-4 weeks after the 
beginning of treatment. If a lower reduction in viral load is observed or it stays above 100,000 cps/mL, 
then the treatment should be adjusted by either adding or switching drugs. After six months it should 
be maintained lower 20 cps/mL. Viral load measurement should be repeated every 4-6 months if 
patient is clinically stable. If viral load returns to 0.3-0.5 log of pre-treatment levels, or there are two 
consecutive blips in its value, then the cART is no longer working and should be changed. The 
appearance of AIDS-defining conditions and the deterioration of the immune system causes the 
progression of the HIV-infection to AIDS.  
 
 The first-line cART comprises different alternatives adapted to each patient. First line cART is 
always composed by three drugs, two of which are nucleoside or nucleotide reverse transcriptase 
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inhibitors (NtRTI; tenofovir/emtricitabine or abacavir/lamivudine) plus one of the following options a 
non-nucleoside reverse transcriptase inhibitor (NNRTI; efavirenz or nevirapine); one protease inhibitor 
(PI; atazanavir or darunavir) boosted with ritonavir; one integrase inhibitor (INI, raltegravir). (EACS, 
2011; DGS, 2012). Occasionally, fist-line regimens needs to be altered - for example in case of 
virological failure, side effects, pregnancy, co-infections - and alternative regiments are adopted 
(EACS, 2011; DGS, 2012). 
 
As a cure to the HIV infection seems not likely to occur in a near future, chronic treatment with anti-
HIV drugs to control the infection is presently unavoidable. Therefore, the greater the knowledge about 
the risks associated with these drugs; greater will be the support for the selection of the best drug for 
the right patient. 
   
1.2 Antiretroviral drugs 
Antiretroviral drugs are distributed by seven classes, according to their mechanism of action in the 
several steps of HIV life cycle (Fig. 1.1). The NRTIs, as abacavir (ABC), act by inhibiting the HIV 
reverse transcriptase enzyme. They are analogues of the naturally occurring deoxynucleotides and 
must be phosphorylated to their pharmacologicaly triphosphate derivates, to later compete with the 
natural deoxyribonucleotides for the incorporation into the growing DNA by cell DNA polymerases. 
Unlike the natural deoxyribonucleotides, NRTI do not have a 3’-hydroxyl group on the deoxyribose 
moiety and, as consequence, following incorporation, the next incoming deoxyribonucleotide cannot 
form the 5’-3’ phosphodiester bond, which is needed to extend the DNA chain, leading to chain 
termination. The nucleotide reverse transcriptase inhibitors (NtRTIs), as tenofovir, are also pro-drugs 
and share with NRTIs the same mechanism of action. The difference between both classes is that 
NtRTs already have one phosphate group and only two additional phosphorylation steps are required 
to be converted into their pharmacological active form (Anderson et al., 2004; Piliero, 2004). The 
NNRTIs, like efavirenz, also inhibit the reverse transcriptase, but in a non-competitive manner.  They 
bind to an allosteric site, near the active site of reverse transcriptase. This binding, changes the 
conformation of reverse transcriptase, distorting the position of the residues which bind DNA,inhibiting 
its polymerization (De Clercq, 2004). The protease inhibitors (PIs) prevent viral replication by inhibiting 
HIV protease, which is the responsible for cleavage precursor polyproteins to structural proteins (eg. 
p24) and functional proteins (eg. reverse transcriptase), preventing the formation of infectious virus 
particles. The only available fusion inhibitor (FI), T-20, acts at the interaction between viral gp120/gp41 
and the receptors of the host cell. After the interaction between gp 120 and CD4 receptor and the 
conformational changes caused by them, the FI bind to gp 41 and prevents the fusion of HIV with the 
host cell membrane. The co-receptors antagonists, specifically the CCR5 receptor antagonists as 
maraviroc, bind to CCR5, blocking the biding of gp120 to the receptor and thus, blocking the binding of 
the virus to the host cell. Lastly, the integrase inhibitors (INIs), as raltegravir inhibit the integrase, 
which is the viral enzyme responsible for the integration of the viral DNA into the host cell genome (De 
Clercq, 2009; Hartman and Buckheit, 2012).  
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Figure 1.1. Schematic overview of the human immunodefiency virus (HIV)-life cycle main steps and 
the targets for antiretroviral drugs. Mechanism of action for the different classes of antiviral drugs 
nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), fusion inhibitors, protease inhibitors, co-receptor 
antagonists and integrase inhibitors throughout the different phases of HIV-life cycle. In: De Clercq (2007).  
 
Despite the irrefutable benefits brought by cART, it is associated with several complications, as the 
increased prevalence of drug-resistant virus strains, the increased incidence of transmission of drug-
resistant virus and the drug toxicity.  For these reasons, the research for new compounds, new drug 
targets and novel therapeutic strategies, such as minimizing antiretroviral toxicity, are essential 
towards successful and safer treatment.  
 
1.3 A focus on abacavir pharmacology 
The NRTI ABC (Fig. 1.2) is a 2’-deoxyguanosine nucleoside analogue. This drug is commercially 
available since 1999, as ABC sulfate (Ziagen®), as part of a two-drug pill (ABC/lamivudine (3TC): 
Kivexa®) and as part of a three-drug pill (ABC/3TC/zidovudine: Trizivir®), for both adults and children, 
with anti-HIV type-1 or type-2 activities (Daluge et al., 1997; Saag et al., 1998; Hervey and Perry, 
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2000). The recommended ABC dosage for adults is 300 mg twice daily (BID) or 600 mg once daily 
(OD). In Kivexa® formulation, ABC is co-formulated with 3TC in a dose of 600 mg for ABC and 300 mg 
for 3TC allowing an OD schedule. However, in those patients with renal insufficiency 3TC dose 
adjustment is required and a BID schedule is recommended. 
 
 
Figure 1.2. Structure of abacavir. 
 
ABC enters cells by non-facilitated diffusion and binds o cytosolic proteins. The pharmacologic 
effect of ABC is achieved after its intracellular conversion to the carbovir thriphosphate (CBV-TP) 
metabolite via a stepwise anabolism, involving enzymes that are not implicated in the phosphorylation 
of the other NRTIs (Faletto et al., 1997). Firstly, ABC is phosphorylated to abacavir 5’-monophosphate 
(ABC-MP) by adenosine phosphotransferase, followed by deamination via a cytosolic enzyme to form 
carbovir 5’-monophosphate (CBV-MP). Following subsequent phosphorylations, carbovir diphosphate 
(CBV-DP) and CBV-TP are generated, via guanylate kinase and nucleoside diphosphate kinase 
activities, respectively. The pharmacologically active metabolite CBV-TP competes with the 
endogenous 2’-deoxyguanosine triphosphate (dGTP) for the incorporation into the nucleic acid chain 
and, after incorporation, terminates DNA chain extension (Fig. 1.3) (Hervey and Perry, 2000; Yuen et 
al., 2008). 
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Figure 1.3. Intracellular conversion of abacavir (ABC) to its pharmacologically active metabolite 
carbovir triphosphate. Phosphorylation steps involve adenosine phosphotransferase, guanylate kinase 
nucleoside diphosphate kinase activities to generate abacavir monophosphate (ABC-MP), carbovir 
monophosphate (CBV-MP) and carbovir triphosphate (CBV-TP). This pharmacologically active metabolite, 
CBV-TP, competes with the endogenous 2’-deoxyguanosine triphosphate for the incorporation into the 
nucleic acid chain.  
 
ABC absolute bioavailability in adults is about 83% (EMEA, 2010; Sivasubramanian et al., 2010). 
Maximum plasma concentration is reached in approximately 0.8 to 1 hour post-dose and ranges from 
4.10 to 5.46 ìg/mL after single 600 mg dose and 2.39 to 11 ìg/mL after a single 300 mg dose (Chittick 
et al., 1999; McDowell et al., 1999; Yuen et al., 2001). This NRTI has a widespread penetration into 
body tissues, including the blood-brain-barrier, reaching the brain, which is a reservoir of HIV-infection. 
This NRTI can also cross the human placenta, allowing concentrations in the newborn at birth, which 
provides protection against HIV-transmission (Best et al., 2006). Unlikely the other drugs of the same 
class, ABC is extensively biotransformed by the liver, with less than 2% being eliminated unchanged 
in the urine (Chittick et al., 1999; McDowell et al., 1999). ABC is biotransformed via two pathways 
comprising a Phase II glucuronidation, mediated by uridine diphosphate glucuronyltransferase (UGT), 
yielding an inactive glucuronide metabolite; and a Phase I oxidation, mediated by alcohol 
dehydrogenase (ADH), yielding an inactive carboxylate metabolite. These metabolites are excreted by 
the kidney, where in combination they account for approximately 66% of the net dose; an additional 
15% of the dose is converted into a number of minor metabolites (McDowell et al., 1999; Hervey and 
Guanylate Kinase  
Nucleoside Diphosphate Kinase  
Inhibition of Viral Replication 
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Perry, 2000; Yuen et al., 2008). ABC metabolites and unchanged ABC account for 83% of the 
administrated dose eliminated in the urine and the remainder is eliminated in the faeces. 
It is well established that ABC can be bioactivated during the formation of the carboxylate 
metabolite (Walsh et al., 2002).  The formation of this metabolite involves a two-step oxidation 
process, via a reactive aldehyde intermediate. The formation of isomers the acid metabolite and the 
ABC in itself through ADH activity led Walsh et al. (2002) to propose a metabolic pathway involving 
double bond migration and epimerization processes upon formation of two putative aldehyde 
intermediates: an unconjugated aldehyde, which rapidly isomerizes into a thermodynamically more 
stable conjugated aldehyde (ABC aldehyde; Fig. 1.4). This conjugated ABC aldehyde is capable of 
reacting with proteins in vitro (Charneira et al., 2011), generating adducts; which potentially can act as 
antigens and be recognized by the immune system, triggering an immune response (Park et al., 
2011a). However, so far this reactive metabolite has eluded detection in humans.  
 
 
 
 
 
 
Figure 1.4. Scheme of abacavir bioactivation and elimination pathways. Metabolic pathway of 
abacavir (ABC) involving the formation of two putative aldehyde intermediates: the unconjugated 
aldehyde, which rapidly isomerizes into the conjugated aldehyde. This conjugated aldehyde is capable of 
reacting with proteins forming protein adducts (Charneira et al., 2011). 
 
1.4 A briefly overview on abacavir toxicity mechanism 
Despite the therapeutic benefits of ABC in HIV-infection treatment, this antiretroviral has been 
associated with several adverse reactions. Nausea is the most frequently reported. In addition, 
vomiting, malaise and fatigue, headache, diarrhea, sleep disorders, cough, anorexia and rash have 
also been described, but in lower frequency. These adverse events tend to be more frequent soon 
after the starting of ABC and are mild or moderate in intensity and transient. The most concerning 
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factor of ABC use is its association with hypersensitivity reactions (HSR) and with myocardial 
infarction (MI). 
 
1.4.1 Hypersensitivity reactions  
HSR has been reported in 3 to 5% of patients, usually occurring within the first 6 weeks of ABC use 
(Clay, 2002) and can lead to drug discontinuation. This adverse reaction is characterized by 
symptoms representative of a multi-organ involvement. It is diagnosed by the manifestation of, at 
least, two of the following symptoms: rash, fever, vomiting, headache, respiratory and gastrointestinal 
symptoms, lethargy, myalgia or arthralgia (Mallal et al., 2002). Usually, these symptoms rapidly 
disappear, after ABC discontinuation. Some patients can be misdiagnosed with respiratory diseases, 
gastroenteritis or reactions to other medications, which may result in a more severe reaction, multi-
organ failure and death. The discontinuation of ABC must be immediate and cannot be re-challenged.  
A strong association between ABC-induced HSR risk and a HLA-B*5701 allele has been described 
in several clinical trials. In the Clinical Trial 1 (PREDICT-1) trial (Mallal et al., 2008) and the Study of 
Hypersensitivity to Abacavir and Pharmacogenetic Evaluation (SHAPE) study (Saag et al., 2008) it 
has been showed that those patients (especially among Caucasians) who carry the HLA-B*5701 allele 
were at higher risk for experiencing an ABC-induced HSR, with a positive predictive value of 47.9% 
and a negative predictive value of 100%. Therefore, current guidelines recommended the performance 
of a prospective test to detect the allele-positive patients, to identify to whom ABC should not be 
prescribe (Nolan, 2009). This prospective test is one of the major successes in the area of 
personalized medicine by mean of pharmacogenetics. However, this test does not predict which 
patients will definitely develop HSR (Mallal et al., 2008), allowing the possibility of different 
mechanisms at the onset of HSR.  
Currently, three major complementary models are considered for these immune-mediated adverse 
reactions: 1) the hapten/prohapten hypothesis (Fig. 1.5) (Uetrecht, 2007); 2) the pharmacologic 
interaction with immune receptors, the p-i hypothesis (Fig. 1.6) (Pichler et al., 2006); and 3) the 
danger model, which is complementar of the hapten hypothesis, adding a secondary signal (eg. an 
infection) (Fig. 1.7) (Pirmohamed et al., 2002). The hapten hypothesis considers that drugs or their 
metabolites are too small to be immunogenic. Instead, they can bind irreversibly to proteins, 
generating covalent adducts, which act as antigens (Uetrecht, 2007). These drug-modified proteins 
are seen as foreign by the immune system, leading to an immune response. Possibly, theses adducts 
are processed by antigen presenting cells (APCs) into peptide fragments, which associate with the 
major histocompatibility complex (MHC) from class I (genes HLA-A, -B and –C) and are presented to 
T-cell receptors (TCR) (Uetrecht, 2007; Bharadwaj et al., 2010; Park et al., 2011b). The p-i hypothesis 
advocates a non-covalent interaction between the drug and the MHC complex and/or the TCR, without 
the involvement of a specific peptide. The danger hypothesis argues that in addition to a signal 1 (the 
biding of the drug or drug-protein adduct to MHC complex), a signal 2 (eg. from injured cells, such as 
those exposed to pathogens or toxins) it is also necessary for activate an immune response. Without 
this signal the response is tolerance to signal 1 (Pirmohamed et al., 2002; Uetrecht, 2007).   
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Figure 1.5. Hapten/prohapten hypothesis. The drug or reactive metabolite covalently binds to protein. 
The modified protein is taken up by antigen presenting cells, processed, and presented through major 
histocompatibility complex (MHC) to helper (CD4) T cells. In: Uetrecht  (2007)  
                                             
 
 
Figure 1.6. Pharmacological interaction (P-i) 
hypothesis. The drug binds directly to the major 
histocompatibility complex leading to an immune 
response to the parent drug. In: Uetrecht (2007).  
Figure 1.7. Danger hypothesis. Together with 
the signal from the hapten hypothesis is also 
necessary a signal 2, which will lead to a co-
stimulation of T-cells. In: Uetrecht (2007). 
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Additionally, a specific model for restricted generation of immunogenic complexes in ABC-induced 
HSR, through the hapten hypothesis, was recently suggested (Bharadwaj et al., 2012), taking into 
account the link to the HLA-B*57:01. Briefly, the covalent modification of a protein, by ABC or a 
metabolite, generates a hapten. This hapten is processed in the cytoplasm by proteasome to produce 
peptide fragments, which are transferred into the endoplasmic reticulum by the transporter associated 
with antigen processing (TAP) (McCluskey et al., 2004), where peptide loading is optimized by tapasin 
(Williams et al., 2002b). Then the peptides are loaded onto HLA-B*5701. The antigen-specific T cells 
recognizing the HLA-B*5701-restricted viral peptide, causing an immune response (Fig. 1.8). 
Functional loss of either TAP or tapasin leads to defective peptide loading and impaired antigen 
presentation (Williams et al., 2002a).  
 
 
Figure 1.8. Hapten hypothesis for a restricted generation of immunogenic complexes in abacavir 
hypersensitivity syndrome on HLA-B*57:01 positive patients. Adapted from Bharadwaj el al. (2012). 
 
1.4.2 Heart toxicity mechanism 
              In addition to the adverse effects described above, long-term ABC exposure has been 
associated with an increased risk of MI (Costagliola et al., 2010; Worm et al., 2010; Islam et al., 2012). 
This association is still controversial, but a recent meta-analysis (Islam et al., 2012) report that 
together with the fact that HIV-patients are at higher risk of devolving cardiovascular disease, ABC is 
the antiretroviral drug associated with greater risk of MI. Also, current guidelines recommend caution 
with ABC administration in patients at higher risk of cardiovascular disease (Thompson et al., 2010) 
and also FDA has been showing concern about this problem, when in March 2011 presented an alert 
for MI risk associated with ABC (FDA, 2011).   
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Based on well documented knowledge of the link between drug aldheyde metabolites and 
cardiotoxicity (Guo and Ren, 2010a), it can be anticipated that ABC aldehyde might play a significant 
role at the onset of ABC-induced heart toxic effects. Nevertheless, this ABC aldehyde has never been 
identified in man, probably due to the lack of suitable methodological approaches. 
 
1.5 Reactive metabolites, protein-adducts and drug toxicity 
The exact mechanism for both cardiotoxicity and HSR associated ABC is not clear. However, ABC 
bioactivation can be involved. The reactive metabolites generated from drug biotransformation are 
usually electrophile species, which react easily with macromolecules (eg. proteins), generating 
adducts. The nucleophilic sites of proteins such as cysteine thiols, lysine amines, histidine imidazoles 
side chains and protein N-terminal amines (Guengerich et al., 2001; Casini et al., 2002) are the 
expected targets of reaction with the electrophilic reactive metabolites.  
Whereas solid proof for the involvement of ABC bioactivation in toxic events induced by this 
antiretroviral has not been found yet, some evidence support this hypothesis: 1) the formation of 
adducts has been implicated in several drug-induced toxic events (Levine and Ovary, 1961; Padovan 
et al., 1996); 2) aldehydes are short-lived and extremely difficult to detect in vivo, but can form stable 
covalent adducts with proteins; 3) aldehydes are often implicated in HSR conditions due to their ability 
to undergo protein modification (Table 1.1) (O'Brien et al., 2005); 4) ADH is present in epithelial 
tissues, including the skin (Lockley et al., 2005) and heart (Estonius et al., 1996); 5) aldehydes are 
often implicated in cardiotoxicity (Carvalho et al., 2004; Luo et al., 2007; Guo and Ren, 2010b). As 
such, it is of unquestionable worth investigating the role of ABC metabolism in the onset of its toxic 
effects (Fig. 1.9).  
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Table 1.1. Examples of drugs activated via aldehyde metabolites and their associated toxicities 
Drugs Use Aldehyde metabolite Toxicity 
Cyclophosphamide Anticancer Acrolein Oxidative stress 
Ifosfamide Anticancer Chloroacetaldehyde Neuro/nephrotoxicity 
Misonidazole Anticancer Glyoxal Polyneuropathy 
Sudoxicam NSAID Glyoxal Hepatotoxicity 
Felbamate Epilepsy Antropaldehyde Hypersensitivity 
Tribromoethanol Anesthetic Tribromoacetaldehyde Hepatotoxicity 
Chloral hydrate Sedative Tribromoacetaldehyde Hepatotoxicity 
Sorbinil 
Aldose redutase 
inhibitor 
Open-chain aldehyde 
intermediate 
Immunotoxicity 
 
 
 
 
Figure 1.9. Drug bioactivation and toxicity. Toxicity may occur through the parent drug accumulation or by 
drug bioactivation through formation of reactive (toxic) metabolites, which, if not detoxified can bind covalently 
to macromolecules.     
 
1.6 Objectives  
The fact that ABC-induced HSR and cardiotoxicity mechanisms are relevant and unclear subjects 
and the necessity for a prospective biomarker of ABC toxicity, especially for preventing chronic events, 
has established the objectives of the present work. ABC bioactivation to an aldheyde metabolite has 
never been identified in man, mainly due to the absence of suitable methodological approach. Our 
initial hypothesis was that this reactive metabolite could be efficiently trapped by N-terminal valine of 
hemoglobin, forming N-terminal-valine-abacavir adducts that could be used to quantify ABC 
bioactivation and plausibly be used as biomarkers of its toxicity. Therefore, the general objective was 
to give evidence for ABC bioactivation in man, through the identification of ABC adducts. To achieve 
the main goal it was firstly necessary to develop an analytical methodology to identify ABC adducts, 
test it and optimize it in an animal model. The identification and quantification of this adducts in HIV-
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infected patients represented the second objective (Fig. 1.10).  Finally, the identification of factors 
which could influence the formation of ABC adducts were also projected. 
 
Specific aims: 
1) Develop a methodology to access ABC adducts 
2) Test the methodology and optimize in an animal model 
3) Identify ABC adducts in HIV-infected patients 
4) Search for factors that may influence the formation of adducts  
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Graphic summary of study work plan. 
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2.1 Materials  
2.1.1 Reagents  
All reagents were acquired from Sigma-Aldrich Co. (St. Louis, MO, USA). The solvents were purified 
and dried when applicable.  
Abacavir (ABC) reference was supplied through the program NIH AIDS Research and Reference 
Reagent Program (abacavir, Cat 4680). ABC sulfate was kindly offered by Dr. Frederick Beland 
(NCTR, Arkansas, USA).  
2.1.2 Enzymes 
Pronase E (EC 3.4.24.31) and leucine aminopeptidase M (EC 3.4.11.2) have been both acquired 
from Sigma-Aldrich Co. (St. Louis, MO, USA). Pronase E solution (0.53 mg/mL) was prepared in 
phosphate buffered saline 10mM (PBS) and leucine aminopeptidase M solution (0.13 mg/mL) was 
prepared in distilled water.  
2.1.3 Consumables 
Silica gel plates 60 F254 from Merck (Darmstadt, Germany) with a thickness of 0.5 mm were 
purchased for performing preparative thin layer chromatography (TLC). The plates were observed by 
ultraviolet light at a wavelength of 254 nm.  
Amicon® Ultra-4 Centrifugal Filter Devices, 30,000 MWCO from Millipore (Billerica, MA, USA) were 
used for isolation of albumin from plasma. 
C-18 Sep-Pak cartridges from Waters (Milford, MA, USA) were used when performing enzymatic 
hydrolysis, for sample concentration. 
2.2 Equipment 
2.2.1 High-performance liquid chromatography (HPLC) 
The semi-preparative and analytical HPLC analysis of ABC-adducts standards was conducted on an 
Ultimate 3000 Dionex (Sunnyvale, CA, USA) system, consisting of a LPG-3400A quaternary gradient 
pump, a diode array spectrophotometric detector and an automatic 8125 Rheodyne (Rohnert Park, 
CA, USA) injector. The semi-preparative analyses were performed on a Luna C18 column (250 × 10 
mm; 5 µm) and the analytical were in a Luna C18 column (250 mm × 4.6 mm; 5 µm), both from 
Phenomenex (Torrance, CA, USA). Data acquisition and processing was performed on the 
Chromeleon® 7.1 software from Dionex (Sunnyvale, CA, USA). 
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The quantification of ABC in plasma by HPLC was performed in a Schimadzu (Kyoto, Japan) 
system, consisting of a LC 9-A solvent delivery pump, a 7725i injector, a SPD-6 AV UV-VIS detector 
and a CTO-10AS VP column oven. Was used a LiChrospher 100 RP-18 (250 x 4 mm; 5 µm) column 
protected by a LiChrospher 100 RP-18e (4 x 4mm; 5 µm) guard-column, both from Merck (New 
Jersey, USA.). Data acquisition and processing were performed on the Shimadzu Class VP 7.X 
software. Isocratic elution was with a mixture of methanol:acetonitrile:potassium dihydrogen 
phosphate 3.7 mM at pH 5.65 (35:10:55; v/v/v), a flow rate of 0.6 mL min at 25 ºC. The UV 
detector was set at a wavelength of 275 nm.  
2.2.2 Liquid Chomatography-Electrospay Ionization-Tandem Mass Spectrometry (LC-
ESI-MS) 
LC-ESI-MS/MS analyses were performed using a ProStar 410 autosampler, two 210-LC pumps, a 
ProStar 335 diode array detector and a 500-MS ion trap mass spectrometer with an ESI ion source 
from Varian, Inc. (Palo Alto, CA, USA). Data acquisition and processing were performed using the 
Varian MS Control 6.9.3 software. The samples were injected via an injector with a 20 µL loop from 
Rheodyne (Rohnert Park, CA, USA). A Luna C18 column (150 mm x 2 mm, 3 µm) from Phenomenex 
(Torrance, CA, USA) was used. The MS was operated in the positive ESI mode. The optimized 
operating parameters were: ion spray voltage, +5.2 kV; capillary voltage, 80 V and RF loading, 70%. 
Nitrogen was used as the nebulizing and drying gas, at pressures of 45 and 10 psi, respectively. The 
drying gas temperature was 350 °C. MS/MS spectra were obtained with an isolation window of 2 Da, 
excitation energy of 1.7 V and excitation time of 10 ms. The MSn spectra were obtained with an 
isolation window of 1.0 Da, excitation energy values of 1.5 and 1.2 V and an excitation time of 10 ms 
(CID up to MS3).  
2.3 Methods 
2.3.1 Preparation of abacavir adduct standards 
2.3.1.1 Abacavir generation from abacavir sulphate  
ABC sulphate powder (600 mg) was dissolved in water (150 mL), followed by the addition of 
potassium hydroxide 1M, to reach pH 8. This solution was then extracted with dichloromethane (4 x 
200 mL). Subsequently, the organic phase was dried with anhydrous magnesium sulfate and filtered. 
The solvent was removed under reduced pressure, affording a white solid and the purity of this 
compound was confirmed by HPLC analysis upon comparison with ABC reference.  
2.3.1.2 Swern Oxidation – Preparation of abacavir conjugated aldehyde 
Oxalyl chloride (78 µL) was added to anhydrous tetrahydrofuran (THF; 3 mL) in a two-necked flask 
under nitrogen at -78 oC, followed by the addition of dimethyl sulfoxide (DMSO; 130 µL). This mixture 
was kept under stirring for 5 min; a suspension of abacavir (200 mg) in anhydrous THF (9 mL) was 
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added and stirred at -78 oC, for 1 h. At this stage, anhydrous triethylamine (507 µL) was added to the 
mixture, the temperature was allowed to rise to 0 oC and stirred for 1 h. Afterwards, distilled water (9 
mL) was added and the mixture was extracted with diethyl ether (3 x 100 mL). Anhydrous magnesium 
sulfate was added to the organic phase to remove water and the solvent was removed under reduced 
pressure. The mixture was purified by preparative TLC [eluted in
 
dichloromethane/methanol (9:1)], 
affording a yellow oil. Identification of the obtained compound was confirmed by analytical HPLC 
analysis upon comparison with a previously prepared standard (Charneira et al., 2011). 
2.3.1.3 Reaction of ethyl valinate with abacavir-conjugated aldehyde 
 A solution of ethyl valinate hydrochloride (40 mg) was prepared in phosphate buffer 50 mM at pH 
7.4 (800 µL) and subsequently treated with sodium hydrogen carbonate (18 mg) for 30 min at 37 oC. 
Following the addition of ABC-conjugated aldehyde solution in THF (0.5 mL) the mixture was 
incubated for 30 min, at 37 oC. Sodium cyanoborohydride (150 mg) was then added and the resulting 
mixture was re-incubated at this temperature overnight. The solvent was removed under reduced 
pressure. 
2.3.1.4 Abacavir-Edman adduct standard   
The mixture afforded at section 2.3.1.3 was dissolved in N,N-dimethylformamide (DMF; 1 mL). 
sodium hydroxide 1M (40 µL) and phenyl isothiocyanate (PTIC; 6 µL) were both added. The solution 
was subsequently stirred for 2 h at 37 oC and then for 1.5 h at 45 oC. Upon cooling to room 
temperature, water (2.5 mL) was added and the solution was extracted with ethyl acetate (2 x 2.5 mL). 
The organic phase was dried under reduced pressure. The ABC-Edman adduct was purified by semi-
preparative HPLC, using the chromatographic conditions described in Table 2.1 and its purity was 
subsequently confirmed upon LC-ESI-MS analysis (Table 2.2).  
 
Table 2.1. Chromatographic conditions for HPLC analysis and isolation of ABC-Edman adduct 
standard.  
 
 
 
Time (min) Formic acid 
0.1% (%) 
Acetonitrile 
(%) 
Flow 
(mL/min) 
UV absorbance 
(nm) 
Temperature 
(oC) 
       0 100 0 
3 254 25 oC 
15 0 100 
17 0 100 
25 100 0 
30 100 0 
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Table 2.2. Chromatographic conditions for LC-ESI-MS/MS analysis of ABC-Edman adduct standard. 
 
 
2.3.2 Identification of abacavir-adducts in Wistar rats  
2.3.2.1 Animal treatment 
The animal handling protocol was approved by the Institutional Animal Care and Use Committee.  
A group of Wistar rats (10-13 weeks old; three males and three females; 274-388 g) were obtained 
from the vivarium of the Faculty of Medical Sciences, New University of Lisbon, where the animals 
were kept under controlled temperature with 12/12h light/dark cycles. They received a standard rodent 
diet and tap water ad libitum. 
The Wistar rats were exposed to ABC, which was suspended in methyl cellulose (0.2% in water) with 
5% of methanol. The rats were administered eight daily intraperitoneal doses of 120 mg ABC/kg body 
weight. An extra group of each gender (two males and two females) received the vehicle alone. Two 
hours after the last treatment, the rats were anesthetized (60 mg/kg of pentobarbital), the chest cavity 
was opened and blood was collected by cardiac puncture into EDTA tubes. The blood samples were 
centrifuged at 3,000 g for 10 min, to separate plasma from blood cells. The samples were aliquoted 
and stored at -80 oC until Hb isolation1.  
2.3.2.2 Isolation of hemoglobin (Tornqvist et al., 2002) 
Aliquots of the red blood cells (400 µL) were washed with sodium chloride 0.9% (3 x 400 µL). The 
saline solution was discarded and Milli-Q water (600 µL) was added to each sample, to promote cell 
lysis.  Next, a hydrochloric acid 50 mM in 2-propanol solution (6mL) was added to 1 mL of the lysate 
and the mixture was centrifuged at 3000 g for 10 min, to remove cell membranes. To the supernatant 
was added iced ethyl acetate (40 mL) to precipitate Hb and the pellet was washed with 20 mL of n-
pentane and finally dried under reduced pressure. 
 
                                                     
1
 The blood samples were already available at the Pharmacology lab. 
Time (min) Formic acid 0.1 
% (%) 
Acetonitrile 
(%) 
Flow   
(mL /min) 
Temperature 
(oC) 
       0 100 0 
0.2 30 
15 0 100 
17 0 100 
25 100 0 
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2.3.2.3 Serum albumin isolation (Lindstrom et al., 1998) 
To the rat plasma (400 µL) was added a saturated ammonium sulfate solution (400 µL). The solution 
was centrifuged at 900 g, 4 oC, for 30 min to remove the immunoglobulins. The supernatant was 
filtered through an Amicon® centrifugal filter with centrifugation at 3800 g, 4 oC, for 20 min and then the 
resulted solution was dried under reduced pressure. 
2.3.2.4 Detachment of N-terminal valine adducts from hemoglobin - N-Alkyl Edman 
degradation (Charneira et al., 2012) 
Each Hb sample (50 mg) from section 2.3.2.2 was dissolved in DMF (1.5 mL), followed the addition 
of sodium hydroxide 1M (65 µL) and PTIC (10 µL). The samples were subsequently stirred for 2 h at 
37 oC and for 1.5 h at 45 oC. Upon cooling to room temperature, water (2 mL) was added and the 
resulted mixtures were extracted with ethyl acetate (2 x 1 mL). The organic phases were dried under 
reduced pressure, resuspended in methanol (50 µL) and were analyzed by LC-ESI-MS/MS using the 
chromatographic conditions described in Table 2.2.       
2.3.2.5 Hydrolysis of serum albumin to amino acids (Tsao and Otter, 1999) 
Serum albumin samples (10 mg) from section 2.3.2.3 were dissolved in PBS 10mM (3.5 mL) and 
solutions of Pronase E (190 µL, 0.53 mg/mL) and leucine aminopeptidase M (80 µL, 0.13 mg/mL) 
were added. The solution was stirred at 37 oC overnight. The enzymatic hydrolysate was concentrated 
in a C-18 Sep-Pak cartridge. The cartridge was conditioned with methanol (3 mL), followed by water (6 
mL). The sample was then loaded, and the cartridge was rinsed with water (1 mL) and methanol (2 
mL). The methanolic eluate was dried under reduced pressure, reconstituted in 60 µL 
acetonitrile/0.1% aqueous formic acid (1:1) and analyzed by LC- ESI-MS/MS through the 
chromatographic conditions described in Table 2.3.  
Table 2.3. Chromatographic conditions used for LC-ESI-MS/MS analysis of rat serum albumin 
hydrolisates. 
Time (min) Formic acid 
0.1 % (%) 
Acetonitrile 
(%) 
Flow 
(mL /min) 
Temperature 
(oC) 
0 95 5 
0.2 30 
5 95 5 
35 30 70 
37 0 100 
45 0 100 
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2.3.2.6 Quantification of abacavir concentration in Wistar rats 
2.3.2.6.1 Preparation of stock and calibration solutions.  
Stock solutions of ABC (1 mg/mL) were prepared in methanol and were stored at -80o C until 
handling.  
Different calibration solutions, to obtain a calibration curve covering the range from 0.005 to 20 mg/L, 
were prepared by dilution of the ABC solution in plasma from rats not exposed to ABC. 
All calibration solutions were heated for 60 minutes at 60 ºC before being submitted to the extraction 
procedure.  
 
2.3.2.6.2 Samples extraction procedure and HPLC analyses.  
A liquid-liquid extraction procedure was performed. Briefly, dichloromethane was added to human 
plasma (500 µL) in a proportion of 1:10, in a 10 mL glass tube. The solution was mixed on a vortex 
mixer and centrifuged at 2 000 g for 5 min, at 4ºC. The organic phase was recovered, and the 
aqueous phase was re-extracted. The two organic phases were combined. The solvent was dried 
under reduced pressure, reconstituted in potassium dihydrogen phosphate 3.7 mM/methanol (1:1; 150 
µL) and 100 µL where injected in the HPLC. 
2.3.2.7 Identification and quantification of abacavir-adducts in HIV-infected patients 
2.3.2.7.1 Enrollment of patients and, demographic and clinical data collection. 
The protocol received prior approval from the Ethics Committee of Centro Hospitalar de Lisboa 
Central, EPE. The patients gave their written informed consent and adherence was controlled through 
a questionnaire. All eligible patients (5 men and 5 women) were adults with documented HIV-infection 
who had received continuous treatment with ABC-containing cART regimens (300 mg twice daily or 
600 mg once daily) for more than 1 month, regardless of past therapeutic history. Exclusion criteria 
were being under 18 years of age, having AIDS-defining conditions or compliance issues. A control 
group (2 healthy volunteers) was also included in the study. From all the patients relevant data were 
collected: age, sex, weight, height, ethnicity, alcohol consumption, injection drug use, smoking habits, 
opportunistic infections, co-morbidities, adverse events, antiretroviral medication, and other analysis 
consider relevant for the study (see Annex I – Case Report Form).  
Blood samples (2 mL) were collected in EDTA tubes. The samples were centrifuged at 3 000 g for 
10 min, 4 oC. The samples of plasma and cells were aliquoted and store at -80 oC until use.  
All patients’ samples were heated for 60 min, at 60ºC, for HIV inactivation, just before handling at 
room temperature. 
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2.3.2.7.2 Abacavir-Edman adduct analysis in HIV-infected patients 
Identification and quantification of the ABC-Edman adduct was conducted in three steps:  a. 
hemoglobin isolation and purification from blood samples (see section 2.3.2.2); b. detachment of N-
terminal valine adducts from haemoglobin (see section 2.3.2.4); and c. analysis of the detached 
adducts by LC-ESI-MS/MS (see section 2.3.2.4). 
For ABC-Edman adducts quantification in patients a stock solution of ABC-adduct standard (1 
mg/mL) was prepared in methanol. Solutions were stored at -20 oC until analyze. Afterwards, different 
calibration solutions, to perform a calibration curve covering the range from 0.25 to 2.5 ng/L, were 
prepared by dilution from the ABC-adduct standard solutions in methanol. 
2.3.2.7.3 Quantification of abacavir plasma concentration in HIV-infected patients 
The quantification of ABC in plasma from HIV-patients was performed in three steps: a) preparation of 
stock and calibration solutions; b) Samples extraction and c) HPLC analysis (see section 2.3.2.6). 
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3.1 Preparation of abacavir adducts standards 
ABC-conjugated aldehyde was prepared upon ABC Swern oxidation, using trietilamine, as base. The 
resulting mixture from Swern reaction was purified by preparative TLC, which allowed the isolation of 
the ABC-conjugated aldehyde with 18% yield. For the preparation of the stabilized adduct (Fig. 3.1), 
ABC-conjugated aldehyde in THF was initially incubated with a solution of ethyl valinate in a 
phosphate buffer 50 mM and then subjected to reduction with sodium cyanoborohydride to stabilize 
the Shciff base formed. The reaction mixture was then submitted to N-Alkyl Edman degradation, using 
the phenyl isothiocyanate as the derivatizing agent (Chevolleau et al., 2007), and following purification 
by semi-preparative HPLC the ABC-Edman adduct was obtained. 
 
 
 
 
Figure 3.1. Formation of abacavir-Edman adduct. Swern oxidation of abacavir into its conjugated 
aldehyde derivative followed by formation of the Schiff base upon reaction with ethyl valinate, which is then 
stabilized by reduction and derivatizated  with phenyl isothiocyanate in a basic medium. 
The purified compound was then analyzed by LC-ESI-MS/MS. The ionic chromatogram exhibited 
only one signal at 9.7 min, confirming the purity of the obtained product, the ABC-Edman adduct 
standard. The identification of this adduct was based upon undistinguishable mass spectra and 
identical retention time, when compared with previously prepared synthetic standard (Fig. 3.2). The 
mass spectra exhibited a protonated molecule at m/z 503 that upon tandem mass fragmentation 
afforded three fragment ions (Fig. 3.3), stemming from loss of the purine moiety (m/z 313), loss of the 
ABC moiety (m/z 235), and cleavage of the purine-cyclopentene bond, with protonation on the purine 
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moiety (m/z 191), respectively. Taken together, all data are in accordance the ones described by 
Charneira et al. (2011), confirming that the isolated product is the ABC-Edman adduct (Charneira et 
al., 2011).  
 
 
 
Figure 3.2. LC-ESI-MS/MS chromatogram of ion m/z 503 from ABC-Edman adduct standard. 
 
 
 
 
Figure 3.3. LC-ESI-MS/MS fragmentation pattern for the ABC-Edman adduct (protonated molecule 
m/z 503). 
3.2 Identification of abacavir-adducts in Wistar rats 
3.2.1 Identification of abacavir-Edman adducts with N-terminal valine of hemoglobin 
To obtain evidence for ABC-conjugated aldehyde ability to modify proteins in vivo, three male and 
three female Wistar rats were treated with eight daily doses of ABC (120 mg/kg body weight) and the 
formation of covalent adducts with the N-terminal valine of Hb was investigated by LC-ESI-MS/MS. 
The LC-ESI-MS/MS analysis of the ion at m/z 503 (corresponding to the protonated molecule of the 
expected adduct) allowed the identification of the N-terminal valine adduct from two (one male and 
one female) out of the six rats. Based on identical retention times (9.7 min) and mass spectra (Fig. 
3.4) when compared with the synthetic standard prepared in section 2.3.1, was possible the 
unequivocal identification of ABC-adducts in Wistar rats. The corresponding MS/MS spectra of ion m/z 
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503 consistently presented three fragment ions, stemming from loss of the cyclopropylaminopurine 
moiety (m/z 313), loss of the abacavir moiety (m/z 235), and cleavage of the purine-cyclopentene 
bond, with protonation on the purine moiety (m/z 191). These signals were absent from all the control 
rat samples. 
 
 
Figure 3.4 LC-ESI-MS/MS analysis from hemoglobin of the Wistar rats exposed to abacavir. A.  
female Wistar rat; B. male Wistar rat and, C. abacavir-Edman adduct standard. 
3.2.2 Identification of abacavir adducts with other amino acids from serum albumin 
To search for other potential targets of ABC-conjugated aldehydes, the isolated rat serum albumin 
was hydrolyzed to free amino acids by an adaptation of reported methodologies, using a combination 
of pronase E and leucine aminopeptidase M, to ensure the endo- and exopeptidase activities required 
for complete hydrolysis (Tsao and Otter, 1999). Following concentration of the enzymatic hydrolysate 
in a C-18 Sep-Pak cartridge, the methanolic eluate was analyzed by LC-ESI-MS/MS to search for the 
presence of plausible adducts with amino acids containing nucleophilic side chains (Fig. 3.5). 
However no adducts were detected in the rat albumin hydrolysate. 
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Figure 3.5 Structures of the covalent adducts expected upon A) Michael addition of cysteine to the 
double bound of abacavir-conjugated aldehyde, B) Shiff base formation, upon lysine addition to the 
abacavir carbonyl group, followed by reductive stabilization.  
 
3.2.3 Quantification of abacavir in plasma from Wistar rats 
Thought analytical HPLC analysis was possible the quantification of ABC concentration in plasma 
from the Wistar rats treated with ABC. Based on identical retention times (8.3 min) when compared 
with the standards solutions was possible the identification of ABC peak, and by a calibration curve 
ABC plasma concentrations were estimated to range between 7.5 and 14.4 mg/L. For rats with ABC- 
Edman adducts the mean ± standard deviation (SD) of ABC concentration was 10.8 ± 1.73 mg/L. In 
those rats which were not identified with adducts, the mean ± SD of ABC concentration was 13.5 ± 5.7 
mg/L. No differences were found (unpaired T-test) between ABC concentration in rats with ABC-
Edman adducts and those in which ABC-Edman adducts were not identified.    
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Figure 3.6. Quantification of abacavir concentration in Wistar rats exposed to abacavir. A, 
Chromatogram obtained following analytical HPLC analysis of a rat exposed to abacavir. The peak 
identified with an arrow corresponds to abacavir; B, Chromatogram from a rat not exposed to abacavir; C, 
Chromatogram from a calibration solution in a concentration of 1.5 mg/L (retention time  8.3 min). 
3.1 Identification and quantification of abacavir-adducts in HIV-infected patients 
3.1.1    Patients demographic and clinical data 
The demographic and clinical data collected from patients who participate in the study are gathered 
in Table 3.1. The patients were 49.7 ± 16.5 years old, half patients were female, and one patient was 
black. Six patients developed adverse events, which were not related with ABC. Six patients 
developed opportunistic infections (acute bronchitis, tuberculosis, pneumonia, candidiasis, syphilis 
and herpes) and 8 developed associated pathologies (major depression, hepatitis C, hypertension, 
diabetes, kaposi sarcoma, dyslipidemia, and hepatomegaly). Though the clinical analysis of function 
liver enzymes it was possible to infer that all the patients had a normal liver function. Three patients 
presented CD4 count lower (< 350 cell.mm3) that the recommended (DGS, 2012). Mostly liver function 
tests where in their normal range.  
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Table 3.1. Demographic and clinical data from HIV–infected patients on abacavir included in the study. 
1
 F, female; M, male. 
2
 C, caucasian; B, black. 
3
 OD, once a day (600 mg); BID, twice a day (300 mg).  
4 cART, combined antiretroviral therapy; 1, lamivudine boosted with a protease inhibitor; 2, lamivudine and tenofovir boosted with a protease inhibitor; 3, lamivudine and 
efavirenz and, 4, lamivudine, tenofovir and efavirenz.   
5
 Y, yes; N, no. 
6
 α, levels are in the normal range; β, levels are out of the normal range. 
AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; γ-GT, gamma-glutamyl transferase; ALP, alkaline phosphatase; LDH, Lactate dehydrogenase.  
 
Patient 
Age 
(years) Sex
1 Ethnicity2 
ABC 
Schedule3 
cART4 
Adverse 
events5 
Opportunistic 
infections5 
Associated 
pathologies 5 
Alcohol 
consumption5 
Smoking 
habit5 
Abused 
drugs5 
CD4 count 
(cell.mm3)6 
AST 
(U/L)6 
ALT 
(U/L)6 
γ-GT 
(U/L)6 
ALP 
(U/L)6 
LDH 
(U/L)6 
Total 
bilirubin 
(mg/dL)6 
A 41 M C OD 1 N Y Y N Y Y α α α α α α β 
B 42 F C OD 1 N Y Y N Y Y α α α α β - α 
C 56 M C OD 2 Y N Y Y Y N β α α α α α β 
D 38 M C BID 3 Y Y Y N Y N α α α α α - α 
E 58 F C BID 1 Y Y Y Y N N β α α β β α β 
F 34 F B OD 2 N Y N N N N α α α α α α α 
G 70 F C OD 2 Y Y Y N N N β α α α α α - 
H 38 F C OD 4 N N Y N N N α α α α β α α 
I 37 M C OD 3 Y N N Y N Y α α α α α α α 
J 83 M C OD 2 Y N Y Y N Y α α α α α α β 
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3.1.2 Abacavir-adduct  analysis in HIV-infected patients 
To obtain evidence for ABC bioactivation to a reactive aldehyde metabolite in man, the presence of 
ABC-Edman adducts with the N-terminal valine of Hb was investigated in ten HIV-infected patients (5 
men and 5 women; Table 3.1).  
Through N-alkyl Edman procedure, for specific detachment of adducts from Hb, and LC-ESI-MS/MS 
analysis was possible to identify, for the first time, ABC-Edman adducts in three patients (two men and 
one woman; Table 3.1, patients A, B and C). LC-ESI-MS/MS analysis of the MS3 transition of the 
protonated molecule [m/z 503 → 313 → 235] allowed the unequivocal identification of this adduct 
based upon undistinguishable mass spectra and identical retention time, when compared with the 
previously prepared synthetic standard in section 2.3.2. Specifically, under the chromatographic 
conditions used, all three positive samples (patients A, B and C) and the synthetic standard 
displayed a signal at 10.5 min, whose MS3 spectrum consistently presented a characteristic fragments 
ion at m/z 235 and 313 (Fig. 3.5). This signal was absent from the control human samples (Fig. 3.5 
B). 
 
 
Figure 3.7. Ionic chromatogram obtained following LC-ESI-MS/MS analysis of the MS3 transition for 
the protonated molecule of the abacavir-valine Edman adduct. A. patient on abacavir; B. healthy 
volunteer not exposed to abacavir, and C. abacavir-Edman adduct standard.   
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Upon calibration curve procedure it was possible to quantify the concentration of ABC-adducts in 
HIV-patients. The three patients (two man and one woman) where were identified the ABC-adducts 
with Hb reach concentrations of 7 fmol/mg (patient A), 2.5 fmol/mg (patient B) and 3.3 fmol/mg of Hb 
(patient C). 
3.1.3 Quantification of abacavir in plasma of HIV-infected patients 
Through analytical HPLC analysis it was possible the quantification of ABC concentration in plasma 
from all the ten patients (Fig. 3.5) included in the study. The ABC plasma concentrations ranged 
between 0.04 and 1.8 mg/L. For patients with ABC-Edman adducts the mean ± SD of ABC 
concentration was 0.2 ± 0.08 mg/L. For patients who were not identified with adducts, the mean ± SD 
of ABC concentration was 0.3 ± 0.2 mg/L. No significant difference were found between the 
concentrations of ABC in patients with ABC-Edman adducts and those without adducts. 
 
 
 
Figure 3.8. Quantification of abacavir concentration in HIV-infected patients. A, Chromatogram 
obtained following analytical HPLC analysis of a HIV-infected patient on abacavir. The peak identified with 
an arrow corresponds to abacavir; B, Chromatogram from plasma of a healthy volunteer and C, 
Chromatogram from a calibration solution in a concentration of 1.5 mg/L (retention time 8.3 min). 
fghjghujk 
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The exact mechanism underlying ABC toxic events is not clear yet. Nevertheless, it has been 
suggested that a reactive metabolite produced via ABC-bioactivation might have a key role at the 
onset of these adverse effects. A decade ago, Walsh et al. (2002) have proposed that ABC-
bioactivation could take place through ADH mediation. However, the confirmation of this hypothesis 
only recently emerged, when Charneira et al. (2011) unrevealed the mechanism of an ABC reactive 
metabolite formation – the conjugated aldehyde. ABC-conjugated aldehyde is a short-lived specie and 
therefore not detectable in man. However, it binds covalently to biological macromolecules (Charneira 
et al., 2011); affording protein adducts which can be quantified in fluids and tissues. So far, there are 
no similar studies in man reported in literature, probably due to the need of cooperation between 
Chemists, who synthesize the bioanalytical standards for assessing bioactivation and electrophile 
metabolites, Pharmacologists and Clinicians who aim at translating basic molecular discoveries in 
valuable tools for clinical practice application. 
 
Initial Strategy 
The drug-protein adducts are broadly studied in blood proteins, mainly albumin and Hb. Both 
proteins are abundant in blood and have a relatively long life span. Based on in vitro studies 
(Charneira et al, 2011) the ABC-conjugated aldehyde was anticipated to react with nuchleophilic 
amino sites of proteins (N-terminal valine of Hb and lysine side chain) via Schiff base formation and 
with sulfhydryl groups of cysteine via Michael addition to the conjugated double bound. These 
residues are primary sites of reaction with electrophiles and a good model to monitor bioactivation. 
(Davies et al., 2009).  
Hb is often used as an easily accessible model for indirect biomonitoring of reactive metabolites, 
particularly by investigating covalent modification at the N-terminal valine residues (Davies et al., 
2009). Given that the pKa values of the α-amino groups from the N-terminal valine residues in 
proteins (ca. 7.80) are close to that of the blood pH (Tornqvist et al., 2002; Davies et al., 2009), a large 
fraction of these residues are unionized and thus have nucleophilic character. For these reasons and 
for the availability of a mild, simple, and sensitive post-modification procedure capable of selectively 
detaching valine adducts from the protein (N-Alkyl Edman degradation), Hb adducts are extensively 
used as biomarkers of exposure to toxicants (Tornqvist et al., 2002; Boysen et al., 2007; Chevolleau et 
al., 2007). 
 
Figure 4.1 Xenobiotic-derived Edman adducts. Schematic representation of the formation of N-terminal 
valine hemoglobin (Hb) adducts with bioactivated xenobiotics and their detachment from the protein upon N-
alkyl Edman degradation. PTIC, phenylisothiocyanate. 
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The detection of N-terminal valine Edman adducts can be achieved by LC-ESI-MS analysis upon 
comparison with a synthetic satandard. Therefore, towards the identification of this adduct in biological 
samples a prior step, involving the synthesis of a standard of ABC-conjugated aldehyde with valine, 
was needed for this purpose.  
Preparation of ABC-Edman adduct standard 
 
The Swern reaction is frequently used as a fundamental procedure to the oxidation of alcohols to 
aldehydes (Crich and Neelamkavil, 2001). Therefore, this reaction was used to perform the oxidation 
of ABC to its conjugated aldehyde (Charneira et al., 2011). The ABC-conjugated aldehyde was then 
incubated with ethyl valinate affording a Sciff base (Fig. 3.1), which is prone to hydrolysis. Therefore a 
subsequent step of reduction, using sodium cyanoborohydride, is needed to afford a stabilized adduct 
which was then subjected to N-Alkyl Edman degradation, allowing the isolation of ABC-Edman adduct 
by semi-preparative HPLC.  
Identification of ABC-Edman adduct in Wistar rats 
 
Thereafter, it was necessary optimize the analytical conditions to detect this adducts in HIV-infected 
patients. Towards this goal we decided to use blood samples from Wistar rats were treated with ABC. 
This decision was based on the fact that these animals could be exposed to a dose of ABC ca.10-fold 
higher than the expected systemic exposure in humans administered with ABC, in order to maximize 
the likelihood of obtaining a detectable response in a short time span, as is expected the metabolism 
in rat is 10 times higher than in man.  
The Wistar rats (three female and three male) were treated with eight daily doses of ABC (120 mg/kg 
body weight), their Hb was isolated, subjected to N-Alkyl Edman degradation and the presence of 
ABC-Edman adducts was screened by LC-ESI-MS/MS.  
The LC-ESI-MS/MS analysis of Hb by comparison with the synthetic standard prepared, allowed the 
identification of ABC-Edman adducts in one female and one male rat, based on identical retention 
times (9.7 min) and MS/MS spectra.  The spectra consistently presented three fragment ions - m/z 
313, m/z 235, and m/z 191 (Fig. 3.4) - and unequivocal identification of ABC-Edman adducts was 
possible.  
These findings represented the first in vivo evidence of both the involvement of the conjugated 
aldehyde intermediate in the metabolic activation of ABC and of its ability to modify covalently the N-
terminal valine residues of Hb.  
Identification of ABC-albumin adducts in Wistar rats 
 
ABC-conjugated aldehyde has also been proved of capable of reacting with N-acetylcysteine in vitro, 
through Michael addition to the conjugated aldehyde (Charneira et al., 2011). This observation was 
consistent with the known propensity of conjugated carbonyls to undergo 1,4-addition by soft 
Protein adducts from the anti-HIV drug abacavir – possible biomarkers of drug toxicity                               4. Discussion 
39
 
nucleophiles, which explains why sulfhydryl groups are considered toxicologically relevant targets for 
α,β-unsaturated aldehydes (LoPachin et al., 2008). Since albumin residues contain a free, solvent-
accessible, sulfhydryl group (Cys-34) (Dooley et al., 2007), they are easily subjected to nucleophilic 
attack. To explore this issue, the rat albumin was hydrolyzed enzymatically to amino acids and 
analyzed by LC-ESI-MS/MS in search for potential products of i) Michael addition of cysteine to the 
conjugated double bond of aldehyde (Fig 3.5A) and ii) lysine addition to the carbonyl group of 
aldehyde with Schiff base formation (Fig 3.5B).  
To search for ABC-cysteine adducts in plasma from the ABC-treated rats, the LC-ESI-MS/MS 
methodology was similar to the one used for the successful detection and characterization of albumin-
cysteine and lysine adducts formed in vitro for another antiretroviral, the NNRTI Nevirapina (NVP) 
(Antunes et al., 2010). Despite the previous evidence that the conjugated aldehyde reacts with 
cysteine and lysine (Charneira et al., 2011) in vitro, none of these adducts were identified in rat 
albumin hydrolysates. A possible explanation for this negative result in the identification of ABC-
lysine/cysteine adducts suggests can be the lower sensitivity of the analytical method for these 
adducts when compared with the one obtained for analyzing N-terminal valine adducts. Indeed, a 
recognized advantage of analyzing N-terminal valine adducts in hemoglobin is the simplicity of sample 
treatment, combined with the selective extraction of these adducts to an organic solvent, which 
minimizes matrix interferences and allows significant adduct enrichment, thereby enabling high levels 
of sensitivity in MS-based analytical methods. Indeed, regardless of the potential toxicological 
relevance of ABC-cysteine/lysine adducts, the efficient monitoring of such adducts in vivo appears 
unlikely at the present stage. Therefore, the analysis of ABC-Edman adducts with N-terminal valine of 
Hb was elected for searching for evidence for ABC-conjugated aldehyde formation in HIV-infected 
patients. 
  
Determination of ABC blood concentration in Wistar rats 
 
In order to understand if the concentration of ABC influences adduct formation, a method for the 
quantification of ABC concentration was developed and tested on the blood of Wistar rats.  The 
methodology for the quantification of ABC concentration in plasma was based in the one described by 
Sudha et al. (2010), but in order to achieve the best sensitivity and selectivity, several parameters were 
modified. For the sample extraction procedure several approaches were screened: extraction after 
precipitation of plasma proteins by methanol and acetonitrile, liquid-liquid extraction with 
dichloromethane and solid-phase extraction. The best results were achieved with the liquid-liquid 
extraction with dichloromethane. The chromatographic conditions were also tested. Several mobile 
phases were tested and in different percentages, methanol:water, acetonitrile:water, methanol: 
phosphate buffer 3.7 mM and methanol:acetonitrile:phosphate buffer 3.7 mM, which was the one with 
the best results. The pump flow and the column temperature were also optimized. Nevertheless, was 
not found any relation between ABC concentration and ABC-Edman adducts formation. This result 
does not mean that there is no relation, once it is necessary to consider, that the number of samples 
(n = 6) was small, which difficult an analysis statistically significant. 
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Identification of ABC-Edman adduct in HIV-infected patients 
 
The ABC-Edman adduct was then investigated in HIV-infected patients, through the optimized 
procedure in rat 1) the isolation of Hb, 2) N-Alkyl Edman degradation and 3) LC-ESI-MS analysis of 
ion m/z 503 through comparison with the ABC-Edman adduct standard. However, using these 
analytical conditions the identification of adducts was very difficult due to matrix interferences. As such 
we had to improve the method selectivity by following the MS3 transition of the protonated molecule 
[m/z 503 → 313 → 235]. Using this improved methodology, the ABC-Edman adduct was 
unambiguously detected in three out of ten patients. These results represent the first report on the 
involvement of a conjugated aldehyde in the metabolic activation of ABC in man. The fact that, only 
30% of the patients had detectable adduct levels implies, as expected, a high degree of inter-
individual variability in ABC activation/detoxification.  
Drug pharmacokinetics (PK) and consequently drug response can be influenced by several factors 
as age, sex, race, drug interactions or pathological states. In fact, those patients had several different 
associated co-pathologies such as hepatitis C virus-infection, hypertension, diabetes or depression. It 
is also important to consider that as immunocompromised persons, HIV-infected patients have a high 
risk of developing several opportunistic infections, tuberculosis or pneumonia. These pathological 
status can by themselves introduce variability in drug pharmacokinetics. Moreover the therapies used 
to treat opportunistic infections can lead to drug interactions. Some patients also had habits like 
smoking, alcohol consumption or drug abuse. All these factors can alter the patient’s 
pharmacokinetics and/or their tolerance to drug-induced toxicity. Moreover, the enzymes responsible 
for ABC metabolism (e.g. ADH) are polymorphic, which also can influence drug PK (Rao et al., 2007). 
Also, HIV infection increases risk of drug toxicity (Koopmans et al., 1995). For instance, glutathione 
(GSH) deficiency has been suggested to be a main factor on the increased frequency of this reactions 
(Koopmans et al., 1995). This antioxidant plays an important role in the detoxification of a variety of 
electrophilic compounds via catalysis by glutathione-S-transferases and glutathione peroxidases.  
Indeed, further work is required to clarify the implications of this interpatient variability for toxicity. 
Other interesting fact is that the three patients that have the ABC-Edman adduct were on an ABC 600 
mg OD schedule. Clearly, an OD regimen has the advantage of therapeutic adherence and a lower 
risk for the development of resistance, but it also raises the risk related to toxicity, especially for drugs 
with a narrow therapeutic window and higher variability degree in its plasma concentrations, as is the 
case of ABC. The 600 mg OD originates, for example, a higher maximum plasma concentration than 
the BID regimen, which can influence the metabolism and consequently toxicity.  
ABC concentration was also quantified in HIV-infected patients, but as in rats no relation between 
patients with adducts and patients without those was found. 
Is well established that bioactivation of drugs is related to adverse drug events and therefore it is 
important to consider this hypothesis for ABC. Several evidence support this hypothesis as: 1) the 
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exposure to aldehydes, either xenobiotic molecules or endogenous intermediates, has been 
associated with induced allergenic responses (O'Brien et al., 2005) and cardiovascular pathologies 
(Luo et al., 2007; Guo and Ren, 2010a); 2) aldehydes have been implicated as reactive and capable 
of covalent binding to proteins and this, in turn, has been suggested to underlying  clinical adverse 
events induced by several drugs (O'Brien et al., 2005). As the case of ethanol, in which acetaldehyde-
protein adducts formation has been proposed as a factor for the immune-mediated hepatitis observed 
with chronic alcohol consumption (Yokoyama et al., 1993); 3) the immunogenic effects of ABC are 
dose-dependent (Norcross et al., 2012b; Ostrov et al., 2012), and 4) not all HLA-B*57:01 carriers 
develop HSR to ABC (Nolan, 2009), thus different mechanisms can be considered. 
The most important concern of ABC use is HSR. Several hypotheses have been proposed for it 
underlying mechanism.(Pirmohamed et al., 2002; Pichler et al., 2006; Uetrecht, 2008). However, none 
of them provided a convincing explanation of how ABC induces adverse reactions through the 
activation of CD8+ cells in a strictly HLA-B*57:01–restricted manner (Chessman et al., 2008). For the 
hapten hypothesis to be applyed, it would be necessary an HLA-specific drug haptenated peptide, 
which until this date had not yet been identified. However, the ABC-conjugated aldehyde metabolite 
indirectly identified in human samples as ABC-Edman adduct has that ability, Adam et al. (2012), 
thought an in vitro study, has refuted the hapten hypothesis for ABC-induced HSR. As the isoform of 
ADH that is involved in ABC metabolism it still unknown, he tested the expression of six different ADH 
isoenzymes (ADH1A, ADH1B, ADH1C, ADH4, ADH5 and ADH6) in various subsets of immune cells. 
Only ADH5 was expressed. They have also shown that even using ADH or proteasome inhibitors, a 
stimulation of ABC-reacting T-cell still exists (Adam et al., 2012). The reactivity of ABC-specific T-cell 
was affected by the inhibition of TAP and the absence of tapasin, suggesting that the ABC 
presentation depends on the MHC class I pathway. These findings had already been described by 
others (Chessment et al, 2008). Nevertheless, the inhibition of TAP and tapasin not only affected the 
peptide loading, but also reduced the expression of HLA molecules on the cell surface. It is possible 
that the effect of TAP and tapasin inhibition is linked to the density of HLA molecules expressed on the 
cell surface rather than to peptide processing and uptake into the endoplasmatic reticulum. Also, for 
the PI model to be applyed, ABC would need to bind to a unique surface area of HLA-B*57:01 that is 
capable of inducing TCR recognition. However, the two residues that distinguish ABC-sensitive HLA-
B*57:01 from ABC-insensitive HLA-B*57:03 are located at the bottom of the HLA-binding groove and 
are unlikely to contact the T-cell receptor (Illing et al., 2012). Finally, the danger model, also does not 
explain its HLA restriction. In the last trimester, several authors have provided evidence that ABC is 
able to bind to HLA-B*5701 and change its structure/specificity, thereby influencing the repertoire of 
self-peptide ligands to be presented (Chessman et al., 2008; Yang et al., 2009; Bharadwaj et al., 
2011; Illing et al., 2012; Norcross et al., 2012a; Ostrov et al., 2012). The authors found specific self-
peptides, which were presented to HLA-B*57:01 only in the presence of ABC, and recognized by T 
cells of hypersensitive patients (Ostrov et al., 2012). Specifically, Illing et al. (2012) reveal that the 
binding of ABC to HLA-B*57:01 alters the F pocket’s binding preference for side chains of the amino 
acids. The authors observed no such change in the peptides that bound to HLA-B*57:03, confirming 
the specificity of ABC-induced HSR to HLA-B*57:01. These evidences refute the hypothesis that ABC 
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adducts can act as haptens and trigger an immune response, but does not exclude it. HSR may be not 
restricted to one mechanism. The predictive test for HLA-B*57:01 has a negative predictive value of 
100% and, as recommended in the clinical practice, all patients on ABC included in the present work 
were negatives and therefore is not expected to develop such reactions. 
 
The molecular mechanisms of ABC-induced cardiotoxicity are even less understood than those of 
HSR. Although an immune-mediated response can be envisioned, metabolic activation of ABC to 
aldehyde intermediates might play a significant role in this context. This hypothesis is consistent with 
the fact that several aldehydes and its ability to site-specific protein modification have been associated 
with several mechanism of cardiotoxicity, as cardiac overexpression of ADH (Guo and Ren, 2010b), 
lipid peroxidation, mitochondrial electron transport, interference on calcium homeostasis (Josephson 
et al., 1991), in the regulation of inflammation, apoptosis, and other cellular signaling (Leonarduzzi et 
al., 2004). 
A well-known example of cardiotoxicity through aldehydes is the ecstasy. Its metabolites are related 
with the production of reactive oxygen species and with the formation of GSH adducts, which can lead 
to GHS depletion (Carvalho et al., 2004). ABC-conjugated aldehydes may be related with these 
mechanisms, through mitochondrial damage, apoptosis or through protein modification, causing 
depletion in protein function and, therefore, leading to myocardial dysfunction, tachycardia, cardiac 
ischemia and heart failure. While more research is needed to clarify the mechanisms underlying ABC-
induced cardiotoxicity there is a plausible role for this ABC Edman adduct as biomarker of ABC-
induced cardiotoxicity, which could be an excellent clinical tool to prevent heart injury on those 
patients on long term ABC use.  
 
Until now there was no experimental evidence that ABC could be bioactivated to a metabolite 
subsisting long enough in humans to undergo protein modification, but in the present study it was 
proved that the conjugated aldehyde formed by ABC metabolism does have that capability. However, 
presenting this evidence does not imply support for an "exclusively-hapten" hypothesis, nor definitely 
explains cardiotoxicity. Clearly more evidence is needed to clarify the mechanism(s) of ABC-induced 
HSR and cardiotoxicity, but summing up, the results reported herein demonstrate that the search for 
causal relationships between the formation of ABC-derived protein adducts and the occurrence of 
ABC-induced toxic events in patients is worth pursuing. Moreover, methodology described in the 
present study, for adduct identification and quantification, is simple, sensitive, accurate, reliable, and 
applicable to high throughput analyses, as required for testing clinical samples. Moreover, this 
approach allowed trapping ABC-conjugated aldehyde in vivo, a significant accomplishment since until 
today it had not been achieved. As such, its biomonitoring is of unquestionable worth for further ABC 
clinical toxicological studies. In the future, the sample size will be enlarged, and the factors that may 
influence ABC-Edman adducts formation (as ADH polymorphisms, time of exposition of ABC and the 
other already mentioned herein) will be evaluated. The adduct concentration will also be related to 
markers of heart function (routine cardiac imaging studies and blood biomarkers) aiming at clarifying 
the adduct role as cardiotoxicity biomarkers.  
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The present study is part of a translational investigation project, which involved different areas of 
knowledge, in a team composed by Clinicians, Pharmacologists and Chemists. My integration into this 
multidisciplinar and deeply committed team, allowed me to contact with different backgrounds from my 
base formation, allowing not only an enormous professional gain but also personal. 
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Annexx I - Case Report Form 
 
 
 
 
 
 
 
 
 
Annex I  
Case Report Form 
    
 
 
 
Por favor, enviar o formulário completo acompanhado das amostras para: 
Departamento de Farmacologia, Faculdade de Ciências Médicas 
Campo dos Mártires da Pátria, 130, 1169-056 Lisboa 
Tel.: 218 803 035    Fax: 218 803 083    E-mail: farmacologia@fcm.unl.pt, sofia.pereira@fcm.unl.pt  
telemóvel Sofia Pereira 96 4243174 
 
 
 
INFORMAÇÃO DO HOSPITAL 
Médico  
 
Hospital  
Telefone 
 
E-mail  
 
CRITÉRIOS DE INCLUSÃO E EXCLUSÃO 
 
 Não Sim 
≥ 18 anos de idade 
 
 
Consentimento informado  
Suspeita de não adesão  
Adesão - cumprir pelo menos 95% da terapêutica antiretroviral 
 
INFORMAÇÃO DO DOENTE 
Doente (n) |___|___|___|___|___|___|___|___| 
Data de nascimento |DD|MM|AA|  
                           
Sexo  F   M    
Peso (Kg) |___|___|         Altura (cm) |___|___|___|   
Etnia:  Caucasiana     Negra    Outra  
Subtipo HIV: _________ 
Consumo de álcool                  N      S           
 
Uso de drogas injectáveis     N      S                                                                  Fumador(a)  N      Y    
 
Reacções adversas                 N       S    
 
Patologias associadas            N            HCV            HBV             Diabetes           Outra   
 
Infecções oportunistas          N            Tuberculose             Outra                                                                                                 
                                                            
 
 
Primeira terapêutica antiretroviral    N      S            
 
 
 
 
 
ESPECIFICAR 
VER ANEXO I 
ESPECIFICAR 
ESPECIFICAR 
ESPECIFICAR ESPECIFICAR 
 Por favor, enviar o formulário completo acompanhado das amostras para: 
Departamento de Farmacologia, Faculdade de Ciências Médicas 
Campo dos Mártires da Pátria, 130, 1169-056 Lisboa 
Tel.: 218 803 035    Fax: 218 803 083    E-mail: farmacologia@fcm.unl.pt, sofia.pereira@fcm.unl.pt  
telemóvel Sofia Pereira 96 4243174 
Terapêuticas antiretrovirais anteriores  
(data de início/fármaco) 
 
|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
Abacavir 
 
Data de início (dia/mês/ano) 
|___|___| |___|___| |___|___| 
mg por toma 
|___|___|___|___| 
Nº de tomas 
|___| 
Co-terapêutica antiretroviral 
Data de início (dia/mês/ano) mg por toma Nº de tomas 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
Outros fármacos Não       Sim  (incluir todos os que tomou no último mês)     
 (incluir fitoterápicos, medicamentos de venda livre, etc.)  
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
NOME DO FÁRMACO |___|___| |___|___| |___|___| |___|___|___|___| |___| 
 
 
 
Parâmetro 
Valor 
Unidade  1 Unidade  2 Data 
    
 
 
 
Por favor, enviar o formulário completo acompanhado das amostras para: 
Departamento de Farmacologia, Faculdade de Ciências Médicas 
Campo dos Mártires da Pátria, 130, 1169-056 Lisboa 
Tel.: 218 803 035    Fax: 218 803 083    E-mail: farmacologia@fcm.unl.pt, sofia.pereira@fcm.unl.pt  
telemóvel Sofia Pereira 96 4243174 
 
 
 
Subpopulações de CD4 |___|___|___|___|___|___|  cel/mm
3  ________ |DD|MM|AA| 
Subpopulações de CD8 |___|___|___|___|___|___|  cel/mm3  ________ |DD|MM|AA| 
Carga viral  
|___|___|___|___|___|___| 
 
cópias/mL 
 ________ 
|DD|MM|AA| 
Hemoglobina  
|___|___|___|___|___|___| 
 g/dL  ________ |DD|MM|AA| 
Plaquetas 
|___|___|___|___|___|___| 
 cel/mm3  ________ |DD|MM|AA| 
Leucócitos  
|___|___|___|___|___|___| 
 g/L  ________ |DD|MM|AA| 
Neutrófilos 
|___|___|___|___|___|___| 
 cel/mm3  ________ |DD|MM|AA| 
Linfócitos  
|___|___|___|___|___|___| 
 cel/mm3  ________ |DD|MM|AA| 
Monócitos  
|___|___|___|___|___|___| 
 cel/mm3  ________ |DD|MM|AA| 
Tempo de protrombina (INR)  
|___|___|___|___|___|___| 
 %  ________ |DD|MM|AA| 
α1-glicoproteína ácida 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Glicémia 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Creatinina 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Ureia 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Albumina 
|___|___|___|___|___|___| 
 g/L  ________ |DD|MM|AA| 
AST 
|___|___|___|___|___|___| 
 U/L  ________ |DD|MM|AA| 
ALT 
|___|___|___|___|___|___| 
 U/L  ________ |DD|MM|AA| 
γ−GT 
|___|___|___|___|___|___| 
 U/L  ________ |DD|MM|AA| 
Fosfatase alcalina |___|___|___|___|___|___|  U/L  ________ |DD|MM|AA| 
 Por favor, enviar o formulário completo acompanhado das amostras para: 
Departamento de Farmacologia, Faculdade de Ciências Médicas 
Campo dos Mártires da Pátria, 130, 1169-056 Lisboa 
Tel.: 218 803 035    Fax: 218 803 083    E-mail: farmacologia@fcm.unl.pt, sofia.pereira@fcm.unl.pt  
telemóvel Sofia Pereira 96 4243174 
LDH |___|___|___|___|___|___|  U/L  ________ |DD|MM|AA| 
Bilirrubina total |___|___|___|___|___|___|  mg/dL  ________ |DD|MM|AA| 
Bilirrubina directa |___|___|___|___|___|___|  mg/dL  ________ |DD|MM|AA| 
PCR |___|___|___|___|___|___|  mg/dL  ________ |DD|MM|AA| 
Ácido hialurónico |___|___|___|___|___|___|  mg/dL  ________ |DD|MM|AA| 
Haptoglobina  
|___|___|___|___|___|___| 
 µg/dL  ________ |DD|MM|AA| 
Alfa2-macroglobulina 
|___|___|___|___|___|___| 
 g/dL  ________ |DD|MM|AA| 
Apolipoproteina A1 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Colesterol total  
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
LDL – col 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
HDL - col 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Triglicéridos 
|___|___|___|___|___|___| 
 mg/dL  ________ |DD|MM|AA| 
Transferrina 
|___|___|___|___|___|___| 
 g/L  ________ |DD|MM|AA| 
Ferro 
|___|___|___|___|___|___| 
 μg/dL  ________ |DD|MM|AA| 
Sódio 
|___|___|___|___|___|___| 
 mmol/L  ________ |DD|MM|AA| 
Potássio 
|___|___|___|___|___|___| 
 mmol/L  ________ |DD|MM|AA| 
MPKA 
|___|___|___|___|___|___| 
   ________ |DD|MM|AA| 
CPK 
|___|___|___|___|___|___| 
 U/L  ________ |DD|MM|AA| 
História Familiar 
Não  Sim  
 
 
Notas 
COLHEITA 
    
 
 
 
Por favor, enviar o formulário completo acompanhado das amostras para: 
Departamento de Farmacologia, Faculdade de Ciências Médicas 
Campo dos Mártires da Pátria, 130, 1169-056 Lisboa 
Tel.: 218 803 035    Fax: 218 803 083    E-mail: farmacologia@fcm.unl.pt, sofia.pereira@fcm.unl.pt  
telemóvel Sofia Pereira 96 4243174 
 
 
 
 
Data da colheita |DD|MM|YY| 
 
 
Responsável pela colheita                                                                                                                                                              . 
 
 
Responsável pela recolha de dados                                                                                                                                         . 
 
 
Antiretrovirais  Dose (mg) 
Frequência 
da dose 
Data de início 
Hora da colheita 
(24 horas) 
Hora última dose 
tomada (24 horas) 
Ingestão de 
alimentos 
com a toma 
Abacavir  OD   BD    |DD|MM|YY| |___|___|:|___|___| |___|___|:|___|___| S     N  
Fármaco1  OD   BD    |DD|MM|YY| |___|___|:|___|___| |___|___|:|___|___| S     N  
Fármaco2  OD   BD    |DD|MM|YY| |___|___|:|___|___| |___|___|:|___|___| S     N  
Fármaco3  OD   BD    |DD|MM|YY| |___|___|:|___|___| |___|___|:|___|___| S     N  
Comentários 
 
